Fortifying the Future: Urological Perspectives on Folic Acid and Spina Bifida Prevention

Introduction: Spina bifida affects 214,000-322,000 pregnancies globally every year. The incidence of this permanently disabling, yet preventable, neural tube defect is 1 in 500 births worldwide but disproportionately 1 in 100 births in low- and middle-income countries. Large-scale food fortification of folic acid, passed in 2023 by the World Health Assembly, provides an economically safe and equitably sustainable public health strategy to prevent the life-long urology-associated manifestations of spina bifida.
Methods: A literature review was conducted to explore the role of folic acid fortification in preventing spina bifida in the context of urological care.
Results: The estimated lifetime direct costs of spina bifida, as it relates to urological care, range between $500,000-$791,900. The goal of urological care in spina bifida patients is to maximize functional status. Folic acid fortification has resulted in fewer cases of spina bifida and consequently fewer pediatric and adult spina bifida-associated urology surgeries. Furthermore, folic acid fortification in the prevention of spina bifida has demonstrated better economic, psychosocial, and health outcomes.
Conclusion: Through research, public health initiatives, and campaigns, widespread folic acid fortification has played a crucial role in reducing spina bifida-related urological morbidity and mortality. Spina bifida is preventable, along with its associated psychosocial, economic, medical, and financial burdens. Currently, there are no global consensus guidelines on spina bifida prevention. Hence, government and healthcare organizations are encouraged to support the World Health Assembly resolution in preventing spina bifida through large-scale folic acid fortification.
Abbreviations: CIC = clean intermittent catheterization; LMIC low- and middle-income country; LUT = lower urinary tract; MMC = myelomeningocele; MOM = management of myelomeningocele; NB = neurogenic bladder; NTD = neural tube defect; SB = spina bifida; UTI = urinary tract infection; VUR = vesicoureteral reflux

spina bifida, spinal dysraphism, folic acid

1. Blencowe H, Kancherla V, Moorthie S, Darlison MW, Modell B. Estimates of global and regional prevalence of neural tube defects for 2015: a systematic analysis. Ann N Y Acad Sci. 2018;1414(1):31-46. [Google Scholar] [Crossref]

2. Mathur PK, Dave P, Fuller SI, et al. Beneficial effects of folic acid fortification in the prevention of Spina Bifida and reducing the orthopaedic procedures: A narrative review of the current literature. Journal of Orthopaedic Reports. 2023/09/01/ 2023;2(3):100175. [Google Scholar] [Crossref]

3. Kancherla V, Botto LD, Rowe LA, et al. Preventing birth defects, saving lives, and promoting health equity: an urgent call to action for universal mandatory food fortification with folic acid. Lancet Glob Health. 2022;10(7):e1053-e1057. [Google Scholar] [Crossref]

4. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet. 1991;338(8760):131-137. [Google Scholar] [Crossref]

5. Bearak J, Popinchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990-2019. Lancet Glob Health. 2020;8(9):e1152-e1161. [Google Scholar] [Crossref]

6. Toivonen KI, Lacroix E, Flynn M, et al. Folic acid supplementation during the preconception period: A systematic review and meta-analysis. Prev Med. 2018;114:1-17. [Google Scholar] [Crossref]

7. https://www.who.int/news/item/29-05-2023-new-wha-resolution-to-accelerate-efforts-on-food-micronutrient-fortification [Google Scholar] [Crossref]

8. Clayton DB, Brock JW 3rd. The urologist's role in the management of spina bifida: a continuum of care. Urology. 2010;76(1):32-38. [Google Scholar] [Crossref]

9. Hughes TL, Simmons KL, Tejwani R, et al. Sexual Function and Dysfunction in Individuals with Spina Bifida: A Systematic Review. Urology. 2021;156:308-319. [Google Scholar] [Crossref]

10. Moussa M, Papatsoris AG, Chakra MA, Fares Y, Dabboucy B, Dellis A. Perspectives on urological care in spina bifida patients. Intractable Rare Dis Res. 2021;10(1):1-10. [Google Scholar] [Crossref]

11. Atta CAM, Fiest KM, Frolkis AD, et al. Global birth prevalence of spina bifida by folic acid fortification status: A systematic review and meta-analysis. American Journal of Public Health. 2016;106(1). doi:10.2105/ajph.2015.302902 [Google Scholar] [Crossref]

12. Wiener JS, Chaudhry R. Neurogenic Lower Urinary Tract Dysfunction. Urol Clin North Am. 2023;50(3):415-432. [Google Scholar] [Crossref]

13. Träff H, Börjesson A, Salö M. Patient-Reported Outcomes of Bladder and Bowel Control in Children with Spina Bifida. Children (Basel). 2021;8(3):209. [Google Scholar] [Crossref]

14. Nseyo U, Santiago-Lastra Y. Long-Term Complications of the Neurogenic Bladder. Urol Clin North Am. 2017;44(3):355-366. [Google Scholar] [Crossref]

15. Hobbs KT, Krischak M, Tejwani R, Purves JT, Wiener JS, Routh JC. The Importance of Early Diagnosis and Management of Pediatric Neurogenic Bladder Dysfunction. Res Rep Urol. 2021;13:647-657. [Google Scholar] [Crossref]

16. Lamin E, Newman DK. Clean intermittent catheterization revisited. Int Urol Nephrol. 2016;48(6):931-939. [Google Scholar] [Crossref]

17. Stein R, Bogaert G, Dogan HS, et al. EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. Neurourol Urodyn. 2020;39(1):45-57. [Google Scholar] [Crossref]

18. Tradewell M, Pariser JJ, Nimeh T, Elliott SP; Neurogenic Bladder Research Group. Systematic review and practice policy statements on urinary tract infection prevention in adults with spina bifida. Transl Androl Urol. 2018;7(Suppl 2):S205-S219. [Google Scholar] [Crossref]

19. Le HK, Cardona-Grau D, Chiang G. Evaluation and Long-term Management of Neurogenic Bladder in Spinal Dysraphism. Neoreviews. 2019;20(12):e711-e724. [Google Scholar] [Crossref]

20. Motta GL, Quiróz Y, Llorens E, Bujons A, Rosito TE. The impact of neurogenic bladder bowel dysfunction in the sexuality of female spina bifida patients. J Pediatr Urol. 2021;17(3):288.e1-288.e6. [Google Scholar] [Crossref]

21. Streur CS, Corona L, Smith JE, Lin M, Wiener JS, Wittmann DA. Sexual Function of Men and Women With Spina Bifida: A Scoping Literature Review. Sex Med Rev. 2021;9(2):244-266. [Google Scholar] [Crossref]

22. Szymanski KM, Roth JD, Hensel DJ, et al. Sexual activity and function of adult men with spina bifida. J Pediatr Urol. 2023;19(3):308.e1-308.e9. [Google Scholar] [Crossref]

23. Gor RA, Elliott SP. Surgical Management of Neurogenic Lower Urinary Tract Dysfunction. Urol Clin North Am. 2017;44(3):475-490. [Google Scholar] [Crossref]

24. Matta R, Wallis CJD, Etches J, et al. Healthcare utilization during transition to adult care in patients with spina bifida A population-based, longitudinal study in Ontario, Canada. Can Urol Assoc J. 2023;17(6):191-198. [Google Scholar] [Crossref]

25. Reynolds RA, Vance EH, Shlobin NA, Bowman R, Rosseau G. Transitioning care for adolescents with spina bifida in the US: challenges for management. Childs Nerv Syst. 2023;39(11):3123-3130. [Google Scholar] [Crossref]

26. Metcalfe PD. Practice-changing publications: Pediatric urology - focus on treatment of spina bifida. Can Urol Assoc J. 2021;15(10):324-325. [Google Scholar] [Crossref]

27. Holmbeck GN, Kritikos TK, Stern A, Ridosh M, Friedman CV. The Transition to Adult Health Care in Youth With Spina Bifida: Theory, Measurement, and Interventions. J Nurs Scholarsh. 2021;53(2):198-207. [Google Scholar] [Crossref]

28. Zurmöhle UM, Homann T, Schroeter C, Rothgerber H, Hommel G, Ermert JA. Psychosocial adjustment of children with spina bifida. J Child Neurol. 1998;13(2):64-70. [Google Scholar] [Crossref]

29. Holmbeck GN, Devine KA. Psychosocial and family functioning in spina bifida. Dev Disabil Res Rev. 2010;16(1):40-46. [Google Scholar] [Crossref]

30. Flewelling KD, Wengryn DM, Buchanan CL, Beltran GP, Vemulakonda VM, Hecht SL. Unexpected challenges faced by caregivers of children with neurogenic bladder: A qualitative study. J Pediatr Urol. 2022;18(4):502.e1-502.e9. [Google Scholar] [Crossref]

31. Oaten M, Stevenson RJ, Case TI. Disease avoidance as a functional basis for stigmatization. Philos Trans R Soc Lond B Biol Sci. 2011;366(1583):3433-3452. [Google Scholar] [Crossref]

32. Kamaludin NN, Muhamad R, Mat Yudin Z, Zakaria R. Barriers and Concerns in Providing Sex Education among Children with Intellectual Disabilities: Experiences from Malay Mothers. Int J Environ Res Public Health. 2022;19(3):1070. [Google Scholar] [Crossref]

33. Grosse SD, Berry RJ, Mick Tilford J, Kucik JE, Waitzman NJ. Retrospective Assessment of Cost Savings From Prevention: Folic Acid Fortification and Spina Bifida in the U.S. Am J Prev Med. 2016;50(5 Suppl 1):S74-S80. [Google Scholar] [Crossref]

34. Copp AJ, Adzick NS, Chitty LS, Fletcher JM, Holmbeck GN, Shaw GM. Spina bifida. Nat Rev Dis Primers. 2015;1:15007. [Google Scholar] [Crossref]

35. Kaufman BA, Terbrock A, Winters N, Ito J, Klosterman A, Park TS. Disbanding a multidisciplinary clinic: effects on the health care of myelomeningocele patients. Pediatr Neurosurg. 1994;21(1):36-44. [Google Scholar] [Crossref]

36. Rodrigues VB, Silva END, Santos MLP. Cost-effectiveness of mandatory folic acid fortification of flours in prevention of neural tube defects: A systematic review. PLoS One. 2021;16(10):e0258488. [Google Scholar] [Crossref]

37. Tilford JM, Grosse SD, Goodman AC, Li K. Labor market productivity costs for caregivers of children with spina bifida: a population-based analysis. Med Decis Making. 2009;29(1):23-32. [Google Scholar] [Crossref]

38. Kancherla V. Neural tube defects: a review of global prevalence, causes, and primary prevention. Childs Nerv Syst. 2023;39(7):1703-1710. [Google Scholar] [Crossref]

39. Khalid SI, Thomson K, Hunter BM, Garcia RM, Bowman R, Lam S. The impact of voluntary folate fortification of corn masa flour on US pregnancies complicated by neural tube defects. Childs Nerv Syst. 2023;39(7):1813-1819. [Google Scholar] [Crossref]

40. Hoddinott J. The investment case for folic acid fortification in developing countries. Ann N Y Acad Sci. 2018;1414(1):72-81. [Google Scholar] [Crossref]

41. Martinez H, Benavides-Lara A, Arynchyna-Smith A, Ghotme KA, Arabi M, Arynchyn A. Global strategies for the prevention of neural tube defects through the improvement of folate status in women of reproductive age. Childs Nerv Syst. 2023;39(7):1719-1736. [Google Scholar] [Crossref]

42. Ismail S, Eljazzar S, Ganji V. Intended and Unintended Benefits of Folic Acid Fortification-A Narrative Review. Foods. 2023;12(8):1612. [Google Scholar] [Crossref]

43. Ghotme KA, Arynchyna-Smith A, Maleknia P, et al. Barriers and facilitators to the implementation of mandatory folate fortification as an evidence-based policy to prevent neural tube defects. Childs Nerv Syst. 2023;39(7):1805-1812. [Google Scholar] [Crossref]

44. Oakley GP Jr. Failure to fortify staple foods with folic acid-still public health malpractice. Childs Nerv Syst. 2023;39(7):1699-1701. [Google Scholar] [Crossref]

45. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed). 1981;282(6275):1509-1511. [Google Scholar] [Crossref]

46. Starowicz J, Cassidy C, Brunton L. Health Concerns of Adolescents and Adults With Spina Bifida. Front Neurol. 2021;12:745814. [Google Scholar] [Crossref]

47. Wiener JS, Frimberger DC, Wood H. Spina Bifida Health-care Guidelines for Men's Health. Urology. 2018;116:218-226. [Google Scholar] [Crossref]

48. Zimmermann MB, Andersson M. Assessment of iodine nutrition in populations: past, present, and future. Nutr Rev. 2012;70(10):553-570. [Google Scholar] [Crossref]

49. Olson R, Gavin-Smith B, Ferraboschi C, Kraemer K. Food Fortification: The Advantages, Disadvantages and Lessons from Sight and Life Programs. Nutrients. 2021;13(4):1118. [Google Scholar] [Crossref]

50. Pattisapu JV, Veerappan VR, White C, et al. Spina bifida management in low- and middle-income countries - a comprehensive policy approach. Childs Nerv Syst. 2023;39(7):1821-1829. [Google Scholar] [Crossref]

• Tribal Child Nutrition and Health in District of Sundargarh: A Public Health Review of ICDS Intervention
• Knowledge, Attitudes and Practices Towards Prostate Cancer Screening Amongst Men Aged 40-60 Years in The Buea Health District: A Cross-Sectional Study
• Compliance with JCI Protocols: A Focus on Employee Safety
• Influence and Involvement of Teachers in Menstrual Hygiene Management of Female Secondary School Students in Kogi State, Nigeria
• A Critical Evaluation of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana in Bihar